Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration approved of deferiprone (Ferriprox Tablets, ApoPharma), as an oral iron chelator to treat patients with transfusional iron overload due to thalassemia syndromes.
Subscribe to our email newsletter
The approval followed previously conducted trials enrolling patients with transfusional iron overload and evidence of inadequate iron removal despite previous treatment with deferoxamine.
The standard of care to treat transfusional iron overload is chelation therapy, where chemical agents that are used to remove heavy metals from the body.
Ferriprox is intended for use when chelation therapy is inadequate.